文献速递临床试验与 GCP基础与转化研究

ATLANTIS:晚期尿路上皮癌化疗后维持靶向治疗的多臂II期生物标志物导向伞式筛选试验

ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer.
PubMed 文献 · Trials · 2020-04-19

ATLANTIS是一项在英国30余家癌症中心开展的随机II期伞式筛选试验,针对晚期或转移性尿路上皮癌患者,在化疗后按生物标志物分组给予维持靶向治疗,主要终点为无进展生存期。该研究旨在为这一中位总生存仅8个月、复发几乎不可避免的人群筛选有效药物,阳性信号药物将进入随机III期试验确认。

要点

  • ATLANTIS是英国首个在尿路上皮癌维持治疗中采用精准医学方法的研究。
  • 试验采用随机II期伞式设计,按生物标志物定义亚组,主要终点为无进展生存期。
  • 有阳性疗效信号的药物将推进至随机III期试验以确认活性。

核心结论

  • ATLANTIS旨在通过生物标志物导向的伞式筛选,为晚期尿路上皮癌化疗后维持治疗寻找有活性信号的新药,并推进至III期确认。

研究设计与样本

  • 随机II期伞式设计筛选试验,在生物标志物定义的晚期尿路上皮癌亚组中评估维持治疗。
  • 研究涉及英国30余家癌症中心,主要终点为无进展生存期。

关键数值与推荐

  • 主要终点为无进展生存期。
  • 有阳性疗效信号的药物将进入随机III期试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic urothelial cancer (UC) is the eighth most common cause of cancer death in the UK. Standard first-line treatment, for most patients, is cytotoxic chemotherapy. Although UC is initially sensitive to chemotherapy, relapse is almost inevitable and outcomes are poor; median overall survival is 8 months. Therefore, there is an urgent need for novel therapies to improve outcomes for this patient group. METHODS: ATLANTIS is a randomised phase II umbrella-design screening trial of maintenance therapy in biomarker-defined subgroups of patients with advanced UC. The primary end point is progression-free survival, and the study involves over 30 UK cancer centres. DISCUSSION: ATLANTIS is the first study in the UK to employ a precision-medicine approach to patients with UC for maintenance treatment. Agents with a positive efficacy signal will proceed to randomised phase III trials to confirm the activity of novel, biologically stratified therapies in UC. REGISTRATION: ATLANTIS trial EudraCT number 2015-003249-25. ISRCTN25859465.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Fulton B, Jones R, Powles T, et al. ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. Trials. 2020. PMID: 32306987. doi:10.1186/s13063-020-04283-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。